BiotechTube

saquinavir/ritonavir + atazanavir/ritonavir

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

HIV Infections

Conditions

HIV Infections

Trial Timeline

Jul 1, 2006 → Jul 1, 2008

NCT ID
NCT00389402

About saquinavir/ritonavir + atazanavir/ritonavir

saquinavir/ritonavir + atazanavir/ritonavir is a approved stage product being developed by Roche for HIV Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00389402. Target conditions include HIV Infections.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00389402ApprovedCompleted

Competing Products

20 competing products in HIV Infections

See all competitors
ProductCompanyStageHype Score
AAVLP-HPV + Placebo2A PharmaPhase 1
25
VN-0200 + PlaceboDaiichi SankyoPhase 1
33
VN-0200Daiichi SankyoPhase 2
52
MicafunginAstellas PharmaPre-clinical
23
amphotericin B liposomal (Ambisome)Astellas PharmaApproved
85
Parenteral micafungin application + Other parenteral antifungal drugsAstellas PharmaPre-clinical
23
Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to EverolimusAstellas PharmaApproved
85
MicafunginAstellas PharmaPre-clinical
23
MicafunginAstellas PharmaPhase 1
33
Micafungin + PlaceboAstellas PharmaPhase 3
77
Cefiderocol + Standard of CareShionogiPhase 2
52
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
33
Xeruborbactam Oral Prodrug + CeftibutenShionogiPhase 1
33
Cefiderocol + Standard of CareShionogiPhase 2
52
Dolutegravir 50 mg twice daily + Dolutegravir placebo twice dailyShionogiPhase 3
77
Xeruborbactam Oral Prodrug + Ceftibuten + Xeruborbactam Oral Prodrug Placebo + Ceftibuten PlaceboShionogiPhase 1
33
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
33
GW810781ShionogiPhase 2
52
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusionShionogiPhase 1
33
CefiderocolShionogiPhase 2
52

Other Products from Roche

EmicizumabApproved
85
rituximab + methotrexate + methylprednisolone + acetaminophen + antihistamineApproved
85
RituximabApproved
85
mycophenolate mofetil [CellCept]Approved
85
5-FU based doublet chemotherapy + bevacizumabApproved
85